Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more
Voyageur Pharmaceuticals Ltd (VYYRF) - Net Assets
Latest net assets as of August 2025: $1.44 Million USD
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VYYRF) has net assets worth $1.44 Million USD as of August 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.67 Million) and total liabilities ($2.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.44 Million |
| % of Total Assets | 39.21% |
| Annual Growth Rate | 7.07% |
| 5-Year Change | 46.88% |
| 10-Year Change | 461.93% |
| Growth Volatility | 252.2 |
Voyageur Pharmaceuticals Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Voyageur Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Voyageur Pharmaceuticals Ltd (2011–2024)
The table below shows the annual net assets of Voyageur Pharmaceuticals Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | $449.96K | -68.66% |
| 2023-11-30 | $1.44 Million | -1.97% |
| 2022-11-30 | $1.46 Million | -23.17% |
| 2021-11-30 | $1.91 Million | +522.25% |
| 2020-11-30 | $306.33K | -59.38% |
| 2019-11-30 | $754.09K | +46.23% |
| 2018-11-30 | $515.68K | +677.88% |
| 2017-11-30 | $-89.24K | -113.31% |
| 2016-11-30 | $670.46K | +737.30% |
| 2015-11-30 | $80.07K | -1.82% |
| 2014-11-30 | $81.56K | -53.67% |
| 2013-11-30 | $176.02K | -20.48% |
| 2012-11-30 | $221.34K | +19.64% |
| 2011-11-30 | $185.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Voyageur Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1083503500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.14 Million | 2030.98% |
| Other Comprehensive Income | $20.93K | 4.65% |
| Other Components | $2.13 Million | 472.37% |
| Total Equity | $449.96K | 100.00% |
Voyageur Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LMS Co. Ltd
KQ:073110
|
$12.98 Million |
|
AdVini S.A.
PA:ALAVI
|
$12.98 Million |
|
Lian Hong Art. Co., Ltd.
TWO:6755
|
$12.99 Million |
|
Kingsmen Creatives Ltd
PINK:KMNCF
|
$12.99 Million |
|
Saga Pure ASA
OL:SAGA
|
$12.98 Million |
|
Dish TV India Limited
PINK:DTTVY
|
$12.97 Million |
|
Health & Life Co., Ltd.
TWO:1781
|
$12.97 Million |
|
Delta Resources Ltd
PINK:DTARF
|
$12.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Voyageur Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,435,785 to 449,958, a change of -985,827 (-68.7%).
- Net loss of 1,707 reduced equity.
- New share issuances of 655,500 increased equity.
- Other comprehensive income increased equity by 9,289.
- Other factors decreased equity by 1,648,909.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.71K | -0.38% |
| Share Issuances | $655.50K | +145.68% |
| Other Comprehensive Income | $9.29K | +2.06% |
| Other Changes | $-1.65 Million | -366.46% |
| Total Change | $- | -68.66% |
Book Value vs Market Value Analysis
This analysis compares Voyageur Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.40x to 0.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-11-30 | $0.20 | $0.08 | x |
| 2012-11-30 | $0.35 | $0.08 | x |
| 2013-11-30 | $0.17 | $0.08 | x |
| 2014-11-30 | $0.08 | $0.08 | x |
| 2015-11-30 | $0.08 | $0.08 | x |
| 2016-11-30 | $0.67 | $0.08 | x |
| 2017-11-30 | $0.00 | $0.08 | x |
| 2018-11-30 | $0.01 | $0.08 | x |
| 2019-11-30 | $0.01 | $0.08 | x |
| 2020-11-30 | $0.00 | $0.08 | x |
| 2021-11-30 | $0.02 | $0.08 | x |
| 2022-11-30 | $0.01 | $0.08 | x |
| 2023-11-30 | $0.01 | $0.08 | x |
| 2024-11-30 | $3.27 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Voyageur Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 5.77x
- Recent ROE (-0.38%) is above the historical average (-82.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -38.64% | 0.00% | 0.00x | 1.11x | $-107.65K |
| 2013 | -25.75% | 0.00% | 0.00x | 1.05x | $-62.93K |
| 2014 | -115.82% | 0.00% | 0.00x | 1.96x | $-102.62K |
| 2015 | -1.85% | 0.00% | 0.00x | 1.12x | $-9.49K |
| 2016 | -7.80% | 0.00% | 0.00x | 1.06x | $-119.37K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-661.83K |
| 2018 | -107.79% | 0.00% | 0.00x | 2.46x | $-607.43K |
| 2019 | -73.24% | 0.00% | 0.00x | 2.13x | $-627.70K |
| 2020 | -371.95% | 0.00% | 0.00x | 4.16x | $-1.17 Million |
| 2021 | -107.62% | 0.00% | 0.00x | 1.35x | $-2.24 Million |
| 2022 | -119.75% | 0.00% | 0.00x | 1.43x | $-1.90 Million |
| 2023 | -97.47% | 0.00% | 0.00x | 1.51x | $-1.54 Million |
| 2024 | -0.38% | 0.00% | 0.00x | 5.77x | $-46.70K |
Industry Comparison
This section compares Voyageur Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Voyageur Pharmaceuticals Ltd (VYYRF) | $1.44 Million | -38.64% | 1.55x | $12.98 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |